Small-molecule BTK inhibitors: From discovery to clinical application

Area of Science:

• Pharmacology and Drug Development
• Oncology
• Immunology

Background:

• Bruton's tyrosine kinase (BTK) inhibitors are small molecules with therapeutic potential for B-cell malignancies and autoimmune diseases.
• The development of BTK inhibitors has evolved significantly since their initial discovery.

Purpose of the Study:

• To review the discovery, design, mechanism of action, and clinical development of BTK inhibitors.
• To highlight key milestones, challenges, and future directions for BTK inhibitor therapy.

Main Methods:

• Literature review of preclinical and clinical studies on BTK inhibitors.
• Analysis of drug design strategies, including high-throughput screening and optimization for selectivity and potency.
• Examination of clinical trial data and emerging research on novel BTK inhibitors.

Main Results:

• The first FDA-approved BTK inhibitor, ibrutinib, revolutionized treatment for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
• Second-generation inhibitors have been developed to overcome resistance, improve pharmacokinetics, and target specific patient groups.
• Challenges in transitioning from preclinical to clinical stages have been identified.

Conclusions:

• BTK inhibitors represent a critical advancement in treating B-cell malignancies and autoimmune disorders.
• Rational drug design and strategic clinical development are crucial for optimizing BTK inhibitor therapies.
• Ongoing research and novel inhibitors promise to expand the role of BTK inhibitors in oncology and immunology.